Inhibitor Therapeutics (INTI) Selling, General & Administrative (2012 - 2026)
Inhibitor Therapeutics (INTI) Selling, General & Administrative (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 582.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 662.10 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.13 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 216.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 593.21 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 347.92 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -196.26 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 247.47 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 161.89 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | 395,033.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 355,070.00 |
| Dec 31, 2025 | 557,866.00 |
| Sep 30, 2025 | 363,426.00 |
| Jun 30, 2025 | 370,150.00 |
| Mar 31, 2025 | 438,493.00 |
| Dec 31, 2024 | 596,455.00 |
| Sep 30, 2024 | 443,575.00 |
| Jun 30, 2024 | 345,371.00 |
| Mar 31, 2024 | 514,458.00 |
| Dec 31, 2023 | 588,356.00 |
| Sep 30, 2023 | 498,763.00 |
| Jun 30, 2023 | 508,468.00 |
| Mar 31, 2023 | 428,326.00 |
| Dec 31, 2022 | 423,635.00 |
| Sep 30, 2022 | 69,987.00 |
| Jun 30, 2022 | 64,654.00 |
| Mar 31, 2022 | 93,500.00 |
| Dec 31, 2021 | 28,684.00 |
| Sep 30, 2021 | 66,248.00 |
| Jun 30, 2021 | 61,685.00 |